Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURATION-1: Exenatide Once Weekly vs Twice Daily in T2DM
NCT00308139Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2006
- Primary completion
- Jul 2008
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of exenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AstraZeneca. Primary endpoints: Change in HbA1c From Baseline to Week 30 and Sub-study Relative Bioavailability of Exenatide at 22 weeks. Started Apr 2006; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00308139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00308139.